We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Inhibitor or Analogue-Based Anti-monkeypox Drug Discovery Solutions
Monkeypox transmission and infection among human populations have become a major international public health concern, as it causes high levels of morbidity and mortality. Discovering reliable strategies to combat monkeypox is essential. For more than ten years, Creative Biolabs has been working in the life science field and providing a full range of anti-virus drug discovery solutions. Potential therapeutic approaches for the development of inhibitor or analogue-based anti-monkeypox agents could be effective in controlling monkeypox virus transmission and infection in the near future.
The key steps of the infectious viral lifecycle include replication, transcription, assembly, and budding from target cells. An essential part of current antiviral therapy is to find clinically effective antiviral compounds, blocking the viral entry into the cells and targeting important viral enzymes such as polymerases, proteases, or neuraminidase, which are responsible for the infectious virus lifecycle. Monkeypox is a poxvirus with double-stranded DNA genomes, replicating in the cytoplasm of infected host cells catalyzed by a virus-encoded DNA polymerase, which could be an antivirals target. Besides, inhibitors of monkeypox-induced DNA replication enzymes, as well as protein kinase inhibitors, may also play an important role in anti-monkeypox.
In addition to the anti-monkeypox inhibitors, nucleoside analogues and nucleotide analogues can also be used as anti-monkeypox therapeutics to prevent viral replication in infected host cells. We can better develop therapeutics by comprehending the antiviral mechanisms of these analogues. Due to their similarity to nucleotides that can be integrated into the growing DNA strand, these analogues are phosphorylated to act as chain terminators, which inhibit viral DNA polymerase and nucleoside/nucleotide reverse transcriptase. However, nucleoside analogues and nucleotide analogues may not be specific to monkeypox DNA. They could also affect the mitochondrial DNA of the hosts, which might have side effects or toxicity.
Therefore, Creative Biolabs takes into account not only the side effects and toxicity of the inhibitors or analogue but also the drug resistance of those compounds when supporting clients in drug discovery and screening.
Fig.1 Replication cycle of a poxvirus. (Kmiec, 2022)
Inhibitor or Analogue-based Anti-Monkeypox Drug Discovery Solutions at Creative Biolabs
The compounds used as inhibitors or analogues are required to have low toxicity and low drug resistance as well as great specificity, thus a high precision drug screening platform is necessary. Creative Biolabs is committed to providing a full range of inhibitor or analogue-based anti-monkeypox drug discovery solutions to meet your requirements from mechanical studies to clinical applications. Leveraging sophisticated high-throughput screening, artificial intelligence, and in vitro and in vivo platforms, we offer a full range of monkeypox products and inhibitor or analogue-based drug discovery solutions against monkeypox. For more information, please do not hesitate to contact us.
Kmiec, D.; Kirchhoff, F. Monkeypox: A New Threat?. International Journal of Molecular Sciences. 2022, 23(14): 7866.